Not FDA-approved2,3Evidence: Large human trialsNot a peptideHormones

MK-6771

Also called Ibutamoren, Ibutamoren mesylate, MK-06771

Not a peptide: a small molecule often looked up alongside peptides.

Key takeaway

MK-677, also called ibutamoren, is a small synthetic compound, not a peptide, that researchers describe as a nonpeptide growth hormone secretagogue: a drug meant to make the body release more growth hormone.1,7 FDA has placed ibutamoren mesylate in category 2 of its compounding lists, for substances that may present significant safety risks, because of the potential for congestive heart failure in certain patients.2 In a randomized trial of 563 people with Alzheimer disease it raised IGF-1 levels but did not slow the disease. No FDA approval is reported in the sources reviewed here.2,5

MK-677 at a glance

Substance typeNot a peptide. A 1998 study describes MK-0677 as a nonpeptide growth hormone secretagogue, and FDA’s substance registry records ibutamoren mesylate as a chemical compound rather than a protein.1,7
What it isA synthetic small-molecule growth hormone secretagogue, recorded by FDA’s substance registry as ibutamoren mesylate and also called MK-677 and MK-0677.1,7
FDA statusNo FDA approval is reported in the sources reviewed here. FDA lists ibutamoren mesylate in category 2 of both of its interim compounding policies, for substances that may present significant safety risks, and its advisory committee voted 13 to 1 in 2024 against adding it to the compounding list.2,3
Human evidenceRandomized trials in older adults: a 12-month trial in 563 people with Alzheimer disease found no effect on the disease, and a hip-fracture trial was stopped early over heart failure.5,6
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is MK-677?

MK-677 is a lab-made compound, not a peptide. A 1998 study describes it as a nonpeptide growth hormone secretagogue, and FDA’s substance registry records it as ibutamoren mesylate, a chemical compound also known as MK-0677.1,7

Its registry record lists the names ibutamoren mesylate, MK-0677 and MK-677.1

How is MK-677 thought to work?

It is designed to prompt the release of growth hormone. In rats, MK-0677 activated nerve cells in the arcuate nucleus of the hypothalamus that help control growth hormone release, according to the 1998 study.7

In the 2008 Alzheimer disease trial it raised blood levels of insulin-like growth factor 1 (IGF-1) by about 60% at 6 weeks and 73% at 12 months.5

What do human studies show?

A randomized, double-blind trial enrolled 563 people with mild to moderate Alzheimer disease for 12 months. MK-677 raised IGF-1 levels but made no significant difference to any measure of the disease, and the authors concluded it was ineffective at slowing its progression.5

A randomized, placebo-controlled trial in 123 older adults recovering from hip fracture found faster walking speed but no improvement in most other measures of physical function. It was terminated early because of a safety signal of congestive heart failure in a limited number of patients.6

The authors of the hip-fracture trial concluded that MK-0677 had an unfavorable safety profile in that population.6

What the evidence base contains

  • Large randomized human trial A randomized, double-blind, multicenter trial in 563 people with mild to moderate Alzheimer disease, which found no difference from placebo on any measure of disease progression over 12 months.5
  • Controlled human trial A randomized, double-blind, placebo-controlled trial in 123 older adults recovering from hip fracture, terminated early because of a safety signal of congestive heart failure.6
  • Animal or laboratory research A rat study showing that MK-0677 activates growth hormone-regulating nerve cells in the hypothalamus.7

Evidence-strength label: Large randomized human trials. How this label is assigned

Is MK-677 FDA-approved?

None of the sources reviewed here reports an approval of MK-677 by FDA.1,2

FDA’s compounding safety-risk page, current as of April 22, 2026, lists ibutamoren mesylate in category 2 under both interim compounding policies: for pharmacies (section 503A) since September 29, 2023, and for outsourcing facilities (section 503B) since December 29, 2022.2

FDA states that it poses significant safety risks because of the potential for congestive heart failure in certain patients, and cites a randomized, placebo-controlled hip-fracture trial that was terminated early because of a potential safety signal of congestive heart failure.2

A Federal Register notice announced the October 29, 2024 meeting of FDA’s Pharmacy Compounding Advisory Committee, which considered ibutamoren mesylate for the 503A bulks list for uses including growth hormone deficiency, osteoporosis, hip fracture, sarcopenia, obesity and Alzheimer disease. FDA proposed that it not be included, and the committee voted 13 to 1 against placing it on the list, according to the minutes.3,4

According to the minutes, several members said the evidence presented did not support effectiveness and safety, and raised concerns about reported fluid retention, congestive heart failure and high blood sugar.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. MK-677 is not among them.8,9

Timeline

  1. A rat study describes MK-0677 as a nonpeptide growth hormone secretagogue acting in the hypothalamus.7
  2. A 563-person randomized trial reports that MK-677 did not slow Alzheimer disease.5
  3. A hip-fracture trial of MK-0677, terminated early over congestive heart failure, is published.6
  4. FDA places ibutamoren mesylate in category 2 under its 503B interim compounding policy, according to its safety-risk page.2
  5. FDA places ibutamoren mesylate in category 2 under its 503A interim compounding policy, according to its safety-risk page.2
  6. FDA’s Pharmacy Compounding Advisory Committee votes 13 to 1 against placing ibutamoren mesylate on the 503A bulks list.3

What is still unknown?

Whether raising growth hormone and IGF-1 with MK-677 benefits any condition: the largest trial reviewed here found no effect on Alzheimer disease.5

How large the heart-failure risk is and who is most at risk; FDA describes the risk in certain patients, and the hip-fracture trial saw it in a limited number of patients.2,6

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for MK-677: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for MK-677 are a bounded selection, not every registration or paper about MK-677. For the years before MK-677 was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list MK-677 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name MK-677 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported; on FDA’s compounding safety-risk list (category 2). A randomized trial of 563 people with Alzheimer disease found no effect, and a hip-fracture trial was stopped early over heart failure. MK-677 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of MK-677?

No FDA approval reported; on FDA’s compounding safety-risk list (category 2). A randomized trial of 563 people with Alzheimer disease found no effect, and a hip-fracture trial was stopped early over heart failure. MK-677 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
4
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 16, 2026

    LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.↗Source date January 27, 2026
  2. Clinical trials · added November 16, 2026

    ClinicalTrials.gov record NCT05364684↗Source date January 6, 2026
  3. Literature metadata · added November 16, 2026

    Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren.↗Source date October 20, 2022

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to MK-677?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

6Selected dated records
15Connected citations
4Populated source years2017–2026
2/4Record lanes present

Registered human studies

Trial composition

2 of 2 selected trial records include at least one phase value; 2 of 2 include a status value in the retained structured contract.

PhasesNot applicable 1Phase 2 1
Status at observationCompleted 2

PubMed bibliography

Publication composition

4 of 4 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 4Research Support, Non-U.S. Gov't 2Case Reports 1Research Support, N.I.H., Extramural 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
6

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 6 dated records

Research hub

Explore the MK-677 evidence record

Open all 6 records →
6Dated records
2Evidence types
6Cited public sources
4Source years

Change ledger

Recently changed for MK-677

Open all 6 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00395291

PeptideScanner retained ClinicalTrials.gov record NCT00395291 at 2026-11-16T17:28:23.215Z. Its registry update date was 2017-02-20, and PeptideScanner's reviewed identity mapping was mk-677.

PeptideScanner change date
November 16, 2026
Cited source date
February 20, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05364684

PeptideScanner retained ClinicalTrials.gov record NCT05364684 at 2026-11-16T17:28:23.215Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was mk-677.

PeptideScanner change date
November 16, 2026
Cited source date
January 6, 2026
Evidence lane
Clinical trials
Record added

Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles.

PubMed lists PMID 31964466 in BMB reports as Journal Article, with publication-date metadata of 2020-03 (month precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2020
Evidence lane
Literature metadata

Official-source collections

Source records for MK-677

Open the full research atlas →
PubMed4

4 with attributed title, venue, publication-date, and type metadata.

  1. LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.Experimental physiology · 2022 11 16
  2. Characterization of equine liver microsome-generated metabolites of growth hormone secretagogue small molecule ibutamoren.Rapid communications in mass spectrometry : RCM · 2021 Dec 15
  3. Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren.Nature communications · 2021 11 04
Explore all selected literature →
ClinicalTrials.gov2

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT05364684Registry update January 6, 2026 · completed at observation
  2. NCT00395291Registry update February 20, 2017 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span February 20, 2017 to January 27, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2,3
  • U.S. Department of Health and Human Services8
Dated updates connected to this profile · 6

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.↗

    PubMed lists PMID 36303408 in Experimental physiology as Case Reports, Research Support, Non-U.S. Gov't, Journal Article, with publication-date metadata of 2022-11-16 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05364684↗

    PeptideScanner retained ClinicalTrials.gov record NCT05364684 at 2026-11-16T17:28:23.215Z. Its registry update date was 2026-01-06, and PeptideScanner's reviewed identity mapping was mk-677.↗

  3. Literature metadata

    Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren.↗

    PubMed lists PMID 34737341 in Nature communications as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-11-04 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Characterization of equine liver microsome-generated metabolites of growth hormone secretagogue small molecule ibutamoren.↗

    PubMed lists PMID 34542924 in Rapid communications in mass spectrometry : RCM as Journal Article, with publication-date metadata of 2021-12-15 (day precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles.↗

    PubMed lists PMID 31964466 in BMB reports as Journal Article, with publication-date metadata of 2020-03 (month precision). PeptideScanner associated the retained record with the identity slug mk-677. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT00395291↗

    PeptideScanner retained ClinicalTrials.gov record NCT00395291 at 2026-11-16T17:28:23.215Z. Its registry update date was 2017-02-20, and PeptideScanner's reviewed identity mapping was mk-677.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Ibutamoren mesylate (MK-677) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  2. 2
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  4. 4
    Federal Register notice 2024-21241 · published 2024-09-18 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026

  5. 5
    Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial (2008) · PMID 19015485 ↗

    Neurology · Official source · Source checked November 16, 2026

  6. 6
    MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study (2011) · PMID 21067829 ↗

    Archives of Gerontology and Geriatrics · Official source · Source checked November 16, 2026

  7. 7
    The nonpeptide growth hormone secretagogue, MK-0677, activates hypothalamic arcuate nucleus neurons in vivo (1998) · PMID 9535057 ↗

    Journal of Neuroendocrinology · Official source · Source checked November 16, 2026

  8. 8
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  9. 9
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026